Walvax Biotechnology unit secures significant government subsidies

Walvax Biotechnology's subsidiary, Yunnan Walvax Biotechnology Co., Ltd., received government subsidies totaling 89,000,000 yuan on October 29, 2025. This funding includes 56,582,300 yuan related to income, representing 39.80% of the company's net profit attributable to shareholders for the most recent audited fiscal year. It also includes 32,417,700 yuan related to assets, accounting for 0.34% of the company's net assets attributable to shareholders.

According to accounting standards, the company plans to record 56,582,300 yuan as "other income" and 32,417,700 yuan as "deferred income." These subsidies are expected to positively impact the company's 2025 operating results, increasing its fourth-quarter profit by 56,582,300 yuan.

The inflow of these funds is anticipated to bolster the company's research and development capital, alleviating pressure on its internal R&D resources. Investors are advised that while this information is based on the company's announcement, the specific accounting treatment and impact on financial data are subject to auditor confirmation.